Industry Insights In…
…Infectious disease diagnostics
Mark Miller |
At a Glance
- High profile public health emergencies have raised awareness of the importance of infectious disease diagnostics, but huge unmet needs still exist, especially in low- and middle-income countries
- Validation of diagnostics is also a big concern; many laboratory tests have not been adequately validated
- It is difficult for lab professionals to decipher which tests have high-quality performance; medical education is needed to support effective decision-making
- There are many exciting innovations in infectious disease testing, but a change in the approach to hospital financing is necessary for the field to progress and for patient care to be improved
If you scour decades’ worth of health stories in consumer literature, you’re likely to see a great number of articles on “groundbreaking” developments in the treatment of a given condition. Fast forward to the present day and, though these (often sensationalist) stories still abound, you are more likely than ever before to read about a new diagnostic test or screening program in your daily newspaper. Much of this attention has been driven by the molecular diagnostics revolution – particularly in oncology, but recent public health emergencies, such as Ebola and Zika, have also had an impact. And though increased awareness of the criticality of good diagnostics is great for the field, there are downsides. We spoke with Mark Miller, Chief Medical Officer of bioMérieux, to find out more...
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Login
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
